1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 2000,4th Edition. American Psychiatric Association; Text Revision.
2. Kaiser S, Heekeren K, Simon JJ. The negative symptoms of schizophrenia: category or continuum? Psychopathology 2011;44:345–353. PMID:
21847001.
3. Altamura AC, Bobo WV, Meltzer HY. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol 2007;22:249–267. PMID:
17690594.
4. Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, et al. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J Clin Psychiatry 2009;70:25–35. PMID:
19192472.
5. Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, et al. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci 2007;257:360–370. PMID:
17629731.
6. Canuso CM, Bossie CA, Turkoz I, Alphs L. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms. Schizophr Res 2009;113:56–64. PMID:
19560322.
7. Schennach-Wolff R, Jäger M, Mayr A, Meyer S, Kühn KU, Klingberg S, et al. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response? Eur Neuropsychopharmacol 2011;21:370–378. PMID:
21255982.
8. Malla A, Payne J. First-episode psychosis: psychopathology, quality of life, and functional outcome. Schizophr Bull 2005;31:650–671. PMID:
16006593.
9. Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 2004;66:125–135. PMID:
15061244.
10. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004;64:1715–1736. PMID:
15257633.
11. Kane JM, Assunção-Talbott S, Eudicone JM, Pikalov A, Whitehead R, Crandall DT. The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials. Schizophr Res 2008;105:208–215. PMID:
18790605.
12. Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69:720–731. PMID:
18370574.
13. Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, et al. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 2009;19:520–532. PMID:
19411165.
14. Salokangas RK, Honkonen T, Stengård E, Koivisto AM. Symptom dimensions and their association with outcome and treatment setting in long-term schizophrenia. Results of the DSP project. Nord J Psychiatry 2002;56:319–327. PMID:
12470304.
15. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544–549. PMID:
10200732.
16. Breier A, Berg PH. The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome. Biol Psychiatry 1999;46:361–364. PMID:
10435201.
17. Weiss EM, Bilder RM, Fleischhacker WW. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology (Berl) 2002;162:11–17. PMID:
12107611.
18. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018–1028. PMID:
12042192.
19. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007;64:1115–1122. PMID:
17909123.
20. Jäger M, Riedel M, Schmauss M, Pfeiffer H, Laux G, Naber D, et al. Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response. Psychiatry Res 2008;158:297–305. PMID:
18280582.
21. Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J. Depression in first-episode schizophrenia. Am J Psychiatry 1993;150:1643–1648. PMID:
8105706.
22. Mauri MC, Moliterno D, Rossattini M, Colasanti A. Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs. Schizophr Res 2008;99:7–12. PMID:
18055177.
23. Altamura AC, Bassetti R, Bignotti S, Pioli R, Mundo E. Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr Res 2003;60:47–55. PMID:
12505137.
24. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82–91. PMID:
12511175.
25. Altamura AC, Buoli M, Serati M. Duration of illness and duration of untreated illness in relation to drug response in psychiatric disorders. Neuropsychiatry (London) 2011;1:81–90.
26. Mu Q, Johnson K, Morgan PS, Grenesko EL, Molnar CE, Anderson B, et al. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res 2007;94:332–341. PMID:
17596915.
27. Agid O, Seeman P, Kapur S. The "delayed onset" of antipsychotic action--an idea whose time has come and gone. J Psychiatry Neurosci 2006;31:93–100. PMID:
16575424.
28. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I (SCID-I), Clinician Version. 1997,Washington, DC: American Psychiatric Press.
29. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276. PMID:
3616518.
30. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990;3:247–251. PMID:
2278986.
31. Guy W. ECDEU Assessment Manual for Psychopharmacology. 1976,Rockville, MD: US Department of Health, Education and Welfare.
32. Monteiro LC, Silva VA, Louzã MR. Insight, cognitive dysfunction and symptomatology in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2008;258:402–405. PMID:
18437275.
33. Bell MD, Lysaker PH, Milstein RM, Beam-Goulet JL. Concurrent validity of the cognitive component of schizophrenia: relationship of PANSS scores to neuropsychological assessments. Psychiatry Res 1994;54:51–58. PMID:
7701028.
34. Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl 2009;438:7–14. PMID:
19132961.
35. Schimmelmann BG, Huber CG, Lambert M, Cotton S, McGorry PD, Conus P. Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res 2008;42:982–990. PMID:
18199456.
36. van Haren NE, Hulshoff Pol HE, Schnack HG, Cahn W, Mandl RC, Collins DL, et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology 2007;32:2057–2066. PMID:
17327887.
37. McGorry PD. The nature of schizophrenia: signposts to prevention. Aust N Z J Psychiatry 2000;34(suppl):S14–S21. PMID:
11129299.
38. Altamura AC, Glick ID. Designing outcome studies to determine efficacy and safety of antipsychotics for 'real world' treatment of schizophrenia. Int J Neuropsychopharmacol 2010;13:971–973. PMID:
20128954.